Editas Medicine Inc. (NASDAQ: EDIT) presented preclinical data showing its gene editing treatment EDIT-401 achieved approximately 90% reductions in LDL ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE